These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19819914)

  • 1. Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
    Joensuu H; Sailas L; Alanko T; Sunela K; Huuhtanen R; Utriainen M; Kokko R; Bono P; Wigren T; Pyrhönen S; Turpeenniemi-Hujanen T; Asola R; Leinonen M; Hahka-Kemppinen M; Kellokumpu-Lehtinen P
    Ann Oncol; 2010 May; 21(5):968-73. PubMed ID: 19819914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
    Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
    Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
    Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
    Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
    Palmeri S; Vaglica M; Spada S; Filippelli G; Farris A; Palmeri L; Massidda B; Misino A; Ferraù F; Comella G; Leonardi V; Condemi G; Mangiameli A; De Cataldis G; Macaluso MC; Cajozzo M; Iannitto E; Danova M
    Oncology; 2005; 68(4-6):438-45. PubMed ID: 16020974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
    Bergh J; Bondarenko IM; Lichinitser MR; Liljegren A; Greil R; Voytko NL; Makhson AN; Cortes J; Lortholary A; Bischoff J; Chan A; Delaloge S; Huang X; Kern KA; Giorgetti C
    J Clin Oncol; 2012 Mar; 30(9):921-9. PubMed ID: 22331954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.
    Makhoul I; Klimberg VS; Korourian S; Henry-Tillman RS; Siegel ER; Westbrook KC; Hutchins LF
    Am J Clin Oncol; 2015 Feb; 38(1):74-9. PubMed ID: 23563210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
    Halim A; Wahba H
    Med Oncol; 2012 Jun; 29(2):454-8. PubMed ID: 21350875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
    Mavroudis D; Saloustros E; Malamos N; Kakolyris S; Boukovinas I; Papakotoulas P; Kentepozidis N; Ziras N; Georgoulias V;
    Ann Oncol; 2015 Jul; 26(7):1333-40. PubMed ID: 25935793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
    Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
    Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
    Schmid P; Krocker J; Schulz CO; Michniewicz K; Dieing A; Eggemann H; Heilmann V; Blohmer JU; Sezer O; Elling D; Possinger K
    Anticancer Drugs; 2005 Jan; 16(1):21-9. PubMed ID: 15613900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.
    Sánchez-Rovira P; Seguí MA; Llombart A; Aranda E; Antón A; Sánchez A; Lomas M; Jaén A; Fernández M; Porras I; Dalmau E; Morales S; de la Haba-Rodríguez J
    Clin Transl Oncol; 2013 Oct; 15(10):810-7. PubMed ID: 23397155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?
    Erten C; Demir L; Somali I; Alacacioglu A; Kucukzeybek Y; Akyol M; Can A; Dirican A; Bayoglu V; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(6):3711-7. PubMed ID: 23886170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
    Gonçalves A; Pierga JY; Ferrero JM; Mouret-Reynier MA; Bachelot T; Delva R; Fabbro M; Lerebours F; Lotz JP; Linassier C; Dohollou N; Eymard JC; Leduc B; Lemonnier J; Martin AL; Boher JM; Viens P; Roché H
    Ann Oncol; 2015 Aug; 26(8):1692-7. PubMed ID: 25943350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
    Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
    Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
    Nielsen DL; Bjerre KD; Jakobsen EH; Cold S; Stenbygaard L; Sørensen PG; Kamby C; Møller S; Jørgensen CL; Andersson M
    J Clin Oncol; 2011 Dec; 29(36):4748-54. PubMed ID: 22084374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
    Tan WW; Allred JB; Moreno-Aspitia A; Northfelt DW; Ingle JN; Goetz MP; Perez EA
    Clin Breast Cancer; 2016 Apr; 16(2):82-6. PubMed ID: 26774555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
    Straver ME; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Wesseling J; Russell NS; Oldenburg HS; Antonini N; Vrancken Peeters MT
    Ann Surg Oncol; 2010 Sep; 17(9):2411-8. PubMed ID: 20373039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
    Sánchez-Muñoz A; Plata-Fernández Y; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Pascual J; Alba E; Sánchez-Rovira P
    Clin Transl Oncol; 2014 Jun; 16(6):548-54. PubMed ID: 24085576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.
    Trédan O; Ménétrier-Caux C; Ray-Coquard I; Garin G; Cropet C; Verronèse E; Bachelot T; Rebattu P; Heudel PE; Cassier P; Chabaud S; Croughs T; Dupont P; Cadore AC; Clapisson G; Delgado A; Bardin-dit-Courageot C; Rigal C; N'Kodia A; Gilles-Afchain L; Morre M; Pérol D; Blay JY; Caux C
    Ann Oncol; 2015 Jul; 26(7):1353-62. PubMed ID: 25851629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.